Diabetes drug combo shows Long-Term safety in new study
NCT ID NCT02622113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in adults with type 2 diabetes. A total of 139 people who had completed a previous 16-week study took part. Researchers tracked side effects, blood sugar control, and weight changes over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Chugoku, Japan
-
Reserch site
Chūbu, Japan
-
Reserch site
Hokkaido, Japan
-
Reserch site
Kanto, Japan
-
Reserch site
Kinki, Japan
-
Reserch site
Kyushu, Japan
-
Reserch site
Tōhoku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- Fig leaf tea may shield kidneys from diabetes damage — a trial puts it to the test
- Can a nasal spray of insulin shield the aging brain from Post-Surgery confusion?
- Smartphone app could improve blood sugar control in type 2 diabetes
- Personalizing kidney treatment: can biomarkers predict who benefits from finerenone?
- Diabetes drug class may change how the bladder behaves